2022
Social Support, social ties, and cognitive function of women with breast cancer: findings from the Women’s Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study
Yang Y, McLaughlin E, Naughton M, Lustberg M, Nolan T, Kroenke C, Weitlauf J, Saquib N, Shadyab A, Follis S, Pan K, Paskett E. Social Support, social ties, and cognitive function of women with breast cancer: findings from the Women’s Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study. Supportive Care In Cancer 2022, 31: 48. PMID: 36525119, PMCID: PMC9758078, DOI: 10.1007/s00520-022-07505-5.Peer-Reviewed Original ResearchConceptsWomen's Health Initiative (WHI) LifeBreast cancerMedian cognitive scoresCognitive functionCognitive scoresBreast cancer stage IMedical Outcomes Study Social Support SurveySocial supportCognitive functioningCancer stage IHigher social support scoresSocial Support SurveyMultivariable quantile regressionHigher cognitive functioningNon-Hispanic whitesSelf-reported cognitive functioningSocial support scoresMajority of participantsBaseline questionnaireCancer cohortHigh riskMethodsThe studyKruskal-Wallis testStage IHigh social support
2017
Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA).
Reinbolt R, Sonis S, Timmers C, Fernández-Martínez J, deAndrés-Galiana E, Hashemi S, Miller K, Ramaswamy B, Wesolowski R, Noonan A, Dewani S, Williams N, Sardesai S, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA). Journal Of Clinical Oncology 2017, 35: 10102-10102. DOI: 10.1200/jco.2017.35.15_suppl.10102.Peer-Reviewed Original ResearchAromatase inhibitor-related arthralgiaAromatase inhibitorsSystematic chart reviewBreast cancer patientsCase-control studyPeripheral blood cellsAsymptomatic patientsChart reviewTherapy switchTreatment initiationTreatment complianceBC patientsGenomic risk predictionCancer patientsBreast cancerStage IPatientsClinical phenotypeBlood cellsSNP groupGermline DNACandidate gene studiesStrong association
2013
Association of osteprotegerin, bone turnover, and bone loss after adjuvant chemotherapy in early-stage breast cancer.
Oostra D, Lustberg M, Pan X, Shapiro C. Association of osteprotegerin, bone turnover, and bone loss after adjuvant chemotherapy in early-stage breast cancer. Journal Of Clinical Oncology 2013, 31: 134-134. DOI: 10.1200/jco.2013.31.26_suppl.134.Peer-Reviewed Original ResearchBone mineral densityFollicle stimulating hormoneEarly-stage breast cancerRapid bone lossBreast cancerBone lossAdjuvant chemotherapyFemoral neckBone resorptionLumbar spineStage ILS bone mineral densityCompensatory responseNegative pregnancy testMonth time pointSubsequent bone resorptionOPG increasePremenopausal womenBone healthBone turnoverMIU/Osteoclast activationMineral densityStimulating hormonePregnancy test